9 Meters Biopharma (9 Meters Biopharma) Quick Ratio

: 0.59 (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. 9 Meters Biopharma's quick ratio for the quarter that ended in Mar. 2023 was 0.59.

9 Meters Biopharma has a quick ratio of 0.59. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for 9 Meters Biopharma's Quick Ratio or its related term are showing as below:

NMTRQ's Quick Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.56
* Ranked among companies with meaningful Quick Ratio only.

9 Meters Biopharma Quick Ratio Historical Data

The historical data trend for 9 Meters Biopharma's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Quick Ratio

Get a 7-Day Free Trial

0.63

0.35

5.68

5.91

1.08

9 Meters Biopharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Quick Ratio	Get a 7-Day Free Trial															4.75	3.36	1.43	1.08	0.59

Competitive Comparison

For the Biotechnology subindustry, 9 Meters Biopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

9 Meters Biopharma Quick Ratio Distribution

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Quick Ratio distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Quick Ratio falls into.

9 Meters Biopharma Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

9 Meters Biopharma's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(33.018	-	0)	/	30.696
	=	1.08

9 Meters Biopharma's Quick Ratio for the quarter that ended in Mar. 2023 is calculated as

Quick Ratio (Q: Mar. 2023 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(9.197	-	0)	/	15.577
	=	0.59

9 Meters Biopharma (OTCPK:NMTRQ) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

9 Meters Biopharma Quick Ratio Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

9 Meters Biopharma (9 Meters Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612

Website

https://www.9meters.com

9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.

Executives

Bethany Sensenig	officer: Chief Financial Officer	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato	director, officer: Chief Executive Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar	officer: Chief Financial Officer	39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice	director	155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish	director, 10 percent owner	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas	director, officer: Executive Chairman	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan	director, officer: President	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky	director	144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior	director, officer: Chief Executive Officer	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff	officer: COO and Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019